Watch for pricing and demand signals as the IPO approaches. Monitor FDA regulatory developments for the cartilage and kidney regeneration platforms, which represent future growth drivers but face significant regulatory hurdles. The company's reliance on parent ROKIT Healthcare for supply, IP, and personnel introduces key-man and related-party risks.
Executive Summary
ROKIT America, Inc. filed Amendment No. 1 to its S-1 registration statement for an IPO of 2,631,579 shares at an estimated price range of $8.50-$10.50 per share, with net proceeds of approximately $21.9 million. The company sells NMN-based dietary supplements and has a licensed AI-driven 3D bioprinting platform for regenerative medicine. Revenue grew 140% YoY to $7.4 million in 2025 with net income of $1.6 million, but the company is heavily reliant on its parent, ROKIT Healthcare, for operations and intellectual property.
Key Financial Metrics
Key Facts
- IPO of 2,631,579 shares at $8.50-$10.50 per share, midpoint $9.50.
- Net proceeds of ~$21.9M (without over-allotment) used 30% for skin regeneration sales/marketing, 20% cartilage, 20% kidney, remainder general corporate.
- Revenue $7.4M in 2025 vs $3.1M in 2024; net income $1.6M vs $0.65M.
- Cash and cash equivalents $184K as of Dec 31, 2025.
- Company has no employees; operations supported via Support Agreement with parent ROKIT Healthcare.
- Dietary supplements (NMN) are current revenue driver; organ regeneration platform licensed from parent is early-stage.
- Underwriters' warrants for 5% of shares at 125% of IPO price; over-allotment of 394,737 shares.
Financial Impact
IPO expected to raise ~$21.9M net proceeds; revenue growth of 140% YoY to $7.4M; net income $1.6M in 2025.
Risk Factors
- Dependence on ROKIT Healthcare for operations, IP, and supply of ORP products.
- Limited cash ($184K) pre-IPO; negative operating cash flow in 2024.
- Regulatory uncertainty for cartilage and kidney regeneration platforms (FDA clearance not obtained).
- No public market for stock; potential volatility post-IPO.
- Concentrated ownership by parent after offering.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001477932-26-002884 |
| Document: 0001477932-26-002884-index.html | 0001477932-26-002884 |
| Document: 0001477932-26-002884.txt | 0001477932-26-002884 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers